Regulatory News:
Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Paris:ALCLS), and Syngene International Ltd, an internationally reputed contract research and manufacturing services (CRAMS) organization and subsidiary of BIOCON Ltd, India's largest biotechnology company by revenue, announced today that they have entered into an agreement to develop novel genetically customized cell lines.
This partnership between Cellectis bioresearch and Syngene will leverage Cellectis' patented technology in genome customization with Syngene's strong biology platform and capabilities to develop novel recombinant and knock-out cell lines for use in oncology- and ADME-Tox-based drug discovery studies.
"This new partnership with Syngene International will enable us to mobilize each organization's expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics" said Marc Le Bozec, Chief Executive Officer, Cellectis bioresearch.
Peter Bains, Chief Operating Officer, Syngene International said, "We are very pleased to enter into this strategic collaboration with Cellectis bioresearch. This is a very exciting R&D arena, employing state-of-the-art technologies, and we are delighted to have the opportunity to support Cellectis' goals through our biology platform at Syngene.'
About Cellectis bioresearch
Established in 2008 as a
subsidiary of Cellectis, Cellectis bioresearch provides life sciences
researchers with genome customization tools and services, such as the
award-winning TALEN® Access™. The company also develops and markets
genetically customized cells with characteristics and performances
adapted to three main markets: drug discovery, gene function studies and
protein production.
For further information, please visit www.cellectis-bioresearch.com
About Syngene International Limited
Established in 1994 as
a subsidiary of Biocon Limited, Syngene is an internationally reputed
custom research and manufacturing company with multi-disciplinary skills
in integrated drug discovery and development, with capabilities in
medicinal chemistry, biology, in vivo pharmacology, toxicology,
custom synthesis, process R&D and formulation development for both small
and large molecules. Over the past 16+ years, Syngene has successfully
partnered with leading players in the global pharmaceutical industry
offering its services across drug discovery/ development continuum.
Syngene has over 1500 scientists and is well-equipped to offer its world
class services to its customers from early stage discovery and
preclinical development through clinical development (Phase I-III) till
commercial manufacturing requirements for small and large molecules in
the most efficient manner in terms of cost, quality and time.
For
further information, please visit www.syngeneintl.com.
Contacts:
Cellectis
Philippe Valachs
Company Secretary
Tel:
+33 (0)1 81 69 16 00
media@cellectis.com
or
Calyptus
Alexis
Breton / Cyril Combe
+33 (0)1 53 65 68 68
cellectis@calyptus.net
